West Nile Virus (WNV) is a mosquito-borne flavivirus with a rapidly expanding global distribution. Infection causes severe neurological disease and fatalities in both human and animal hosts. The West Nile viral protease (NS2B-NS3) is essential for post-translational processing in host-infected cells of a viral polypeptide precursor into structural and functional viral proteins, and its inhibition could represent a potential treatment for viral infections. This article describes the design, expression, and enzymatic characterization of a catalytically active recombinant WNV protease, consisting of a 40-residue component of cofactor NS2B tethered via a noncleavable nonapeptide (G 4 SG 4 ) to the N-terminal 184 residues of NS3. A chromogenic assay using synthetic para-nitroanilide (pNA) hexapeptide substrates was used to identify optimal enzyme-processing conditions (pH 9.5, I < 0.1 M, 30% glycerol, 1 mM CHAPS), preferred substrate cleavage sites, and the first competitive inhibitor (Ac-FASGKR-H, IC 50 ϳ1 M). A putative three-dimensional structure of WNV protease, created through homology modeling based on the crystal structures of Dengue-2 and Hepatitis C NS3 viral proteases, provides some valuable insights for structure-based design of potent and selective inhibitors of WNV protease.
The West Nile Virus (WNV) 1 was first detected in a woman living in the West Nile region of Uganda almost 70 years ago (1) . WNV is a member of the Flaviviridae family that also includes hepatitis C, Kunjin, yellow fever, Dengue, St. Louis, and Japanese encephalitis viruses (1) . WNV is transmitted via mosquitoes from avian reservoir hosts to vertebrate dead-end hosts that include humans and horses. Endemic in humans in parts of Africa, Europe, and the Middle East, previous viral outbreaks were mostly detected as asymptomatic infections or mild febrile disease states (2) . However, recent outbreaks in Israel (1998), Romania (1996) , and the United States (1999) (3) have been associated with more serious neurological pathology and fatal infections. During the last 5 years, WNV has spread rapidly throughout the United States (4,156 infections and 284 deaths in 44 states in 2002, 9862 infections and 264 deaths in 2003), 2 Canada, and Mexico, as well as appearing recently in the United Kingdom (5) . This rapid global spread, even through developed countries, has prompted widespread implementation of prevention strategies. No vaccines or therapeutic treatments for WNV infections are yet available.
Like other members of the Flaviviridae family, WNV contains a single-stranded, positive-sense RNA genome, which encodes three structural proteins (capsid (C), membrane (M), envelope (E)), and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) (1, 3) . The genome is initially translated as a single, large polyprotein precursor. Post-translational cleavages of the viral polyprotein precursor in the cytoplasm of host-infected cells are necessary to produce the separate structural and functional viral proteins that are essential for assembly of new viral progeny. These cleavages are performed by both host enzymes (including signalases and furin) and by a viral protease encoded by the N-terminal-third of NS3 (Fig. 1 ). This NS3 viral protease, which is a trypsin-like serine protease with a functional catalytic triad (His 51 , Asp 75 , Ser 135 ), is absolutely essential (along with viral-encoded cofactor NS2B) for viral replication and is itself autocatalytically cleaved from the polypeptide precursor. By analogy with the homologous Dengue virus NS3 protease, for which our truncation studies had previously shown that a 40-residue hydrophilic domain of NS2B is necessary for catalytic activity of the NS3 protease, (6) we infer below that a similar sequence within the WNV NS2B is likely necessary for catalytic activity of the WNV NS3 protease. The remainder of NS2B encodes 3 hydrophobic domains, believed to be involved in membrane association and localization of the enzyme to convoluted membrane regions on the endoplasmic reticulum (7) . The structure of WNV NS3 protease is unknown, but there are reported crystal structures for related NS3 proteases of hepatitis C virus (HCV) (8) and Dengue virus (DEN2) (9) . The structure of the latter protease was however determined in the absence of the NS2B cofactor and was thus an inactive enzyme.
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ʈ To whom correspondence should be addressed. Fax: 61-733462101; E-mail: d.fairlie@imb.uq.edu.au. 1 The abbreviations used are: WNV, West Nile Virus; CAPS, 3-(cyclohexylamino)propanesulfonic acid; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate; DCM, dichloromethane; DIPEA, N,N-diisopropylethylamine; DMF, N,N-dimethylformamide; ESMS, electrospray mass spectrometry; HCV, hepatitis C virus; HRMS, High Resolution electrospray mass spectrometry; IPTG, isopropyl-D-thiogalactopyranose; MES, 2-(N-morpholino)ethanesulfonic acid; MOPS, 4-morpholinepropanesulfonic acid; PMSF, phenylmethylsulfonyl fluoride; R t , retention time; TLCK, tosyl-L-lysine chloromethyl ketone; HIV, human immunodeficiency virus; HPLC, high performance liquid chromatography; pNA, para-nitroanilide. prevent viral replication. Precedents for inhibitors of viral proteases being potential antiviral drugs lie in the success of inhibitors of proteases of the human immunodeficiency viruses (HIV), currently the most effective treatments for humans with HIV/AIDS (10, 11) , and in the early promise being shown by inhibitors of the NS3 protease of hepatitis C virus (12) . This article describes the design and construction of a catalytically active recombinant WNV NS2B-NS3 protease enzyme construct, the characterization of factors that influence enzymatic processing of short synthetic chromogenic substrates containing para-nitroanilide (pNA), the first reported inhibitor of WNV protease, and the development of a three-dimensional homology-modeled structure of the WNV NS3 protease based on the known crystal structures of Dengue NS3 protease and HCV NS3 protease complexed with cofactor NS4A. It is expected that the recombinant protease cofactor construct, chromogenic assay, and homology structure might be useful for future structure-based design of even more potent and selective inhibitors of the WNV NS3 protease. Such inhibitors might form the basis for developing an antiviral therapy for the treatment of WNV infections.
EXPERIMENTAL PROCEDURES
General Methods-Protected amino acids and resins were obtained from Auspep, Novabiochem and PepChem. Trifluoroacetic acid, piperidine, DIPEA, DCM, and DMF (peptide synthesis grade) were purchased from Auspep. All other materials were reagent grade unless otherwise stated. Crude peptides were purified by reverse-phase HPLC on a Vydac C18, 10 -15 m, 300 Å, 50 ϫ 250 mm) column, using a gradient mixture of solvent (A) 0.1% trifluoroacetic acid/water and (B) 0.1% trifluoroacetic acid/10% water/90% acetonitrile. Analytical HPLC was performed on a Waters system equipped with a 717 plus autosampler, 660 controller and a 996 photodiode array detector, using a reversephase Phenomenex Luna C18, 5 m, 100 Å, 250 ϫ 4.6-mm column. Purified peptides were characterized by analytical HPLC (linear gradient 0 -100% B over 30 min), mass spectrometry, and NMR. The molecular weight of the peptides (1 mg/ml) was determined by electrospray mass spectrometry on a Micromass LCT mass spectrometer. 1 H NMR spectra were recorded on samples containing 4 mM peptide in Me 2 SO-d 6 (550 l) on a Bruker Avance 600 spectrometer at 298 K. Proton assignments were determined by TOCSY (80 ms mixing time), DQF-COSY, ECOSY, and NOESY (350 ms mixing time) spectra using the sequential assignment method (13) . All spectra were processed on Silicon Graphics R10000 or R12000 workstations using XWINNMR 2.6 (Bruker BioSpin GmbH, Rheinstetten, Federal Republic of Germany).
Plasmid Construction-WNV (strain NY99 -4132)-infected Vero cell RNA was generously provided by R. A. Hall and D. J. Nisbet (University of Queensland, Australia). cDNA was generated using the WNV NS3pro.RHindIII reverse primer (5Ј-GCCCCCAAGCTTACAGCATCT-CAGGTTCGAAT-3Ј; restriction sites are underlined), which was then used as template in the generation of the WNV NS3pro and the WNV CF40.Gly.NS3pro constructs. WNV NS3pro was generated by a PCR reaction using the primers WNV NS3pro.FBamH1 5Ј-GCCCCTGGAT-CCGGTGGCGTATTGTGGGATACT-3Ј and WNV NS3pro.RHindIII 5Ј-GCCCCCAAGCTTACAGCATCTCAGGTTCGAAT-3Ј. WNV CF40.GLY. NS3PRO was generated in two separate PCR reactions employing the primer pairs WNV CF40.FBamH1 5Ј-CGATGAC GGCGGATCCACAG-ATATGTGGATTGAGAGAACG-3Ј/WNV CF40.Gly.R 5Ј-CCCGCCTCC-ACCACTACCTCCCCCGCCCTTCCAAGGAGCACCTGGATC-3Ј and WNV NS3proGly.F 5Ј-GGCGGGGGAGGTAGTGGTGGAGGCGGGGG-AGGCGTATTGTGGGA TACT-3Ј/WNV NS3pro.RHindIII 5Ј-GCCCCC-AAGCTTACAGCATCTCAGGTTCGAAT-3Ј to generate PCR products encoding the essential 40 residue cofactor domain of NS2B and the 184 residue NS3pro genes, flanked with partial glycine linker sequences. These PCR products were then joined by overlapping PCR using the outer primers WNV CF40.FBamHI and WNV NS3pro.RHindIII. The resulting PCR products, designated WNV NS3pro and CF40.Gly.NS3pro, comprised the 184 residue NS3 protease domain alone and the 40 residue essential cofactor domain of NS2B linked to the 184 residue NS3 protease via a flexible nonapeptide glycine linker (Gly 4 SerGly 4 ), respectively. These were then digested with BamHI and HindIII and cloned into pQE9. The identity of these constructs, designated pQE9 WNV NS3pro and pQE9 WNV CF40.Gly.NS3pro was confirmed by automated sequence analysis.
Enzyme Expression and Purification-The pQE9 WNV CF40.-Gly.NS3pro vector was used to allow high level, inducible expression of N-terminal hexahistidine-tagged recombinant proteins. Cultures of Escherichia coli strain SG13009 transformed with the expression plasmids were grown in 500 ml of LB medium containing 100 g/ml ampicillin and 25 g/ml kanamycin at 37°C until OD 600 reached 0.5. Expression of the recombinant protein was induced by the addition of isopropyl-␤-D-thiogalactopyranose (IPTG) to a final concentration of 0.3 mM and incubated for an additional 3 h at 22°C. The cells were then harvested by centrifugation and stored at Ϫ20°C.
For protein purification, the cell pellets were thawed and resuspended in 5 ml of lysis buffer (50 mM HEPES, pH 7.5, 300 mM NaCl,10 mM imidazole, 5% glycerol) per 1 g of wet pellet. To prevent proteolytic cleavage of protein during cell lysis and purification the following protease inhibitors were added to give the final concentration of 1 g/ml aprotinin, 1 g/ml leupeptin, 1 g/ml benzamide, 1 mM PMSF, and 10 g/ml TLCK. The resuspended cells were lysed by three passes through a French Press at a pressure of 1000 Pascals and then centrifuged at 27,000 ϫ g for 20 min at 4°C. The recombinant proteases, tagged at the N terminus by a hexahistidine sequence, were purified by affinity chromatography on a Ni 2ϩ -nitrilotriacetic acid-agarose column (Qiagen). A 1-cm column was pre-equilibrated with 30 ml of column buffer (50 mM HEPES, pH 7.5, 300 mM NaCl, 10 mM imidazole, 5% glycerol), and then the resin was removed and mixed with the supernatant of the cell lysates. These mixtures were then incubated at 4°C on a shaker for 30 min to allow the His-tagged protein to bind to the Ni 2ϩ resin. The columns were re-packed and washed with 30 ml of column buffer containing 20 mM imidazole before eluting the protein into 6 ϫ 1 ml fractions with column buffer containing 100 mM imidazole. The pre-and post-IPTG induction samples, soluble and insoluble fractions, and the elution fractions were analyzed by 12% SDS-PAGE.
Substrate Synthesis-The pNA substrates corresponding to the native WNV NS3 protease cleavage sites Ac-DPNRKR-pNA (NS2A-NS2B), Ac-LQYTKR-pNA (NS2B-NS3), Ac-FASGKR-pNA (NS3-NS4A), and Ac-KPGLKR-pNA (NS4A-NS5) were synthesized by a reported method (15 ϩ ϭ 691.3886, found 691.3896. Enzymatic Characterization-The recombinant WNV protease (WNV CF40.Gly.NS3pro) was assayed against four hexapeptide substrates corresponding to P6-P1 of known endogenous cleavage sites NS2A-NS2B (Ac-DPNRKR-pNA), NS2B-NS3 (Ac-LQYTKR-pNA), NS3-NS4A (Ac-FASGKR-pNA), NS4B-NS5 (Ac-KPGLKR-pNA) with a chromogenic pNA group in the P1Ј position. Cleavage of the pNA chromophore from the peptide substrates by the WNV protease produced a detectable color change at 405 nm, allowing protease activity to be measured. The assay was conducted on a 96-well plate with a final reaction volume of 200 l containing buffer (plus glycerol and CHAPS detergent for optimal processing), 0.5 M recombinant protease, and 500 M substrate at 37°C. After preincubation in separate wells (10 min, 37°C), catalysis was initiated by mixing substrate with the enzyme buffer solution by automatic shaking. The optical density was measured at 405 nm every 30 s for 10 min in a SpectraMax 250 reader, and the average change in mOD/min was calculated. pH dependence was determined over the range 5.5-12.0 using 0.5 M enzyme, 500 M substrate (Ac-FASGKR-pNA), incubation temperature 37°C, constant ionic strength (I ϭ 5 mM), final volume 200 l, for 50 mM buffer (MES (pH 5.5-7.0), MOPS (pH 6.5-8.0), Tris (pH 7.5-9.5), CAPS (pH 10.0 -11.0)) containing NaCl, glycerol, CHAPS detergent.
Glycerol dependence was determined by assaying environments of increasing glycerol content, from 0 to 50% glycerol (5% increments) in the final volume of 200 l. Glycerol dependence assays contained buffer with NaCl, glycerol, CHAPS detergent, 0.5 M enzyme, 500 M substrate (Ac-FASGKR-pNA), constant ionic strength (I ϭ 5 mM, NaCl), at 37°C in a final volume 200 l.
Ionic strength dependence was determined for 0 -200 mM NaCl in buffer (with glycerol, CHAPS), 0.5 M enzyme, 500 M substrate (Ac-FASGKR-pNA), 37°C in the final volume of 200 l.
Initial reaction velocities were monitored continuously at 405 nm on a SpectraMax® 250 spectrophotometer, and then interpreted using the accompanying SoftMax™ Pro software, both from Molecular Devices Corporation. Subsequent assays for K m determination were performed under optimal pH, glycerol and ionic strength conditions as determined by interpretation of the previous pH, glycerol, and ionic strength assays via SoftMax™ Pro and GraphPad Prism® software.
Optimal assaying conditions, found to be 30% glycerol, pH 9.5, no added NaCl, were used to determine K m and k cat values measured for the four pNA-peptide substrates at concentrations ranging from 100 to 3000 M. Results were graphed using GraphPad Prism® version 4.0a for Macintosh, GraphPad Software, San Diego, CA (www.graphpad. com), and kinetic parameters calculated from weighted nonlinear regression assuming Michaelis-Menten kinetics
. Data are reported as the means of triplicate measurements Ϯ S.E.
Homology Modeling-West Nile Virus NS3 protease homology models were generated using the structures of the Dengue virus NS3 protease without ligand (pdb1BEF), (9) and with Bowman-Birk inhibitor (pdb1DF9, subunit B), (9) and hepatitis C virus NS3 protease with bound cofactor (pdb1A1Q) (8) . Models were generated using the Modeler and the Homology module within the InsightII molecular modeling system (17) . All modeling was performed using Silicon Graphics R10000 workstations.
Sequences were aligned using Align 2D, Structure Alignment (Homology Module, InsightII) and ClustalW alignment (18) . Secondary structure predictions were conducted using web-based PsiPred prediction for each of the three NS3 protease sequences (19) . Electrostatic potential mapping was performed on the WNV NS3 protease model using the Delphi module in InsightII (20) . A four-residue P3-P1Ј substrate (Thr-Lys-Arg-Gly) was docked into the active site of a homology model of the WNV NS3 protease using GOLD v2.1 (21) . A specified distance constraint between substrate residue Arg (P1) and WNV protease Tyr 150 (S1), as well as distance and hydrogen bond constraints between substrate residue Thr (P3) and WNV protease Gly 153 (S3) were used based on our understanding of protease-inhibitor interactions (22, 23) . 3 The docked structures were ranked for best fitting conformations using GOLD 2.1 (21) .
RESULTS

Design of a Catalytically
Active WNV Protease-The single serine protease within the flaviviral WNV RNA genome provides an ideal starting point and therapeutic target for research into the design and development of a WNV serine protease inhibitor. The first step in designing a catalytically active WNV protease was based on our previous work on the Dengue-2 viral protease, for which we identified a minimum sequence of 184 residues from the NS3 protease (NS3pro) and 40 residues from the NS2B cofactor (CF40) that are necessary for catalytic processing of substrates (6, 25) . In that work we created a catalytically active protease construct by fusing CF40 to NS3pro separated by various linkers, the most active construct involving a nonapeptide linker (GGGGSGGGG) as a replacement for the normal NS2B-NS3A cleavage sequence.
Alignment of the WNV and Dengue virus NS2B-NS3 se-quences ( Fig. 2 ) indicated 53% sequence identity (exact amino acid match) and 79% sequence similarity (hydrophilicity/phobicity) within the 184 residues of NS3pro. This homology, including conserved catalytic residues His 51 (H), Asp 75 (D), and Ser 135 (S), and oxyanion residue Gly 133 (G), gave us confidence in our alignment. Residue Gly 178 in WNV NS3 was not present in Dengue-2 virus NS3. Alignment of the NS2B cofactor domains displayed 33% sequence identity (exact amino acid match) and 75% sequence similarity (high and low chemical similarity). These sequence comparisons suggested that, by analogy with the Dengure-2 NS2B-NS3 protease, a catalytically active sequence for WNV NS2B-NS3 protease might similarly constitute 40 residues from the NS2B cofactor and 184 residues from NS3, connected via a nonapeptide linker G 4 SG 4 (abbreviated as Gly) in place of the normal NS2B-NS3 cleavage site sequence. We designated the putative catalytic protease construct as WNV CF40.Gly.NS3pro. A recombinant construct was also generated consisting of the 184 residue NS3 protease domain in the absence of the NS2B cofactor domain to confirm that activity was dependent on the correct association of the cofactor, as was previously shown for the Dengue virus equivalent construct (6) . We designated this construct WNV NS3pro.
Expression and Purification of WNV NS3pro and WNV CF40.Gly.NS3pro-The first experimental aim was to express and purify a recombinant WNV NS3 protease domain and a catalytically active recombinant WNV protease based on the recombinant Dengue-2 virus NS3 protease (6) . The homologous WNV recombinant constructs (WNV NS3pro and WNV CF40.Gly.NS3pro) were produced and cloned into the pQE9 expression vector. The sequence of these constructs and their insertion into pQE9 was confirmed by automated sequence analysis.
The pQE9 vector was used because it allowed a high level of expression, inducible with the addition of IPTG. The addition of an N-terminal hexahistidine tag enabled ready purification by Ni 2ϩ affinity chromatography. The SDS-PAGE expression profile of pQE9 WNV NS3pro and pQE9 WNV CF40.Gly.NS3pro are shown in Fig. 3, A and B , respectively and the Ni 2ϩ affinity chromatography of purified WNV CF40.Gly.NS3pro is shown in Fig. 3C . Fig. 3A shows a major band at ϳ23 kDa, present only in the bacterial lysates prepared after induction with IPTG. This band was attributed to recombinant WNV NS3pro as it is under the control of the T5 promoter and correlates approximately with the theoretical size of WNV NS3pro predicted by Vector NTI of 21 kDa. As we had observed previously with Dengue virus NS3pro (6) following extraction, the majority of the expressed product was found in the insoluble pellet fraction, with very little present in the soluble fraction. Fig. 3B shows a major band at ϳ32 kDa, present only in the bacterial lysates prepared after induction with IPTG. This band was attributed to recombinant WNV CF40.Gly.NS3pro as it is under the control of the T5 promoter and correlates approximately with the theoretical size of WNV CF40.Gly.NS3pro predicted by Vector NTI of 27 kDa. The majority of this expressed product was present in the soluble fraction, indicating that the recombinant protein was likely to be folded correctly. Both recombinants were subsequently purified from the soluble fractions by Ni 2ϩ affinity chromatography. Because of the low level of recombinant WNV NS3pro in the soluble fraction relatively poor recoveries were obtained. Fig. 3C however shows that the WNV CF40.Gly.NS3pro recombinant (ϳ30 kDa) was recovered and purified efficiently. The difference in molecular weight estimations between B and C was likely due to the use of prestained and non-prestained molecular weight markers, respectively. The two additional bands were attributed to products of autocatalytic cleavage, since they were not present in the purification of an inactive recombinant S135A mutant enzyme (data not shown) consistent with these fragments being dependent on proteolytic activity. These products were not expected to have an effect on processing of synthetic peptide substrates as the rate of autocatalytic cleavage is several orders of magnitude lower than that of peptide substrate cleavage and the substrate concentration is far in excess of enzyme concentration.
Proteolytic Activity-In vivo there are at least seven known post-translational cleavage sites that are processed by WNV protease in the cytoplasm of infected host cells (Fig. 1) . Amino acid residues corresponding to those cleavage sites are displayed in Fig. 4 . We chose P6-P1 hexapeptides from four of these sequences to construct putative substrate analogues terminating in a chromophore (para-nitroanilide) at P1Ј. The putative substrate sequences were Ac-DPNRKR-pNA (NS2A-2B), Ac-LQYTKR-pNA (NS2B-NS3), Ac-FASGKR-pNA (NS3-NS4A), and Ac-KPGLKR-pNA (NS4B-NS5). These potential substrates were to be used to characterize proteolytic activity of WNV CF40.Gly.NS3pro under a variety of assay conditions, culminating in an optimum set of conditions that could be used for more detailed kinetic analysis, and ultimately for inhibitor screening. A preliminary comparison of these four substrates suggested that Ac-FASGKR-pNA was processed fastest and with the highest efficiency (k cat /K m ), so that particular substrate was used in the following investigation of factors that influence substrate processing by the protease. Sufficient purified WNV NS3pro was obtained to assess its enzymatic properties against Ac-FASGKR-pNa and was the found not to cleave the substrate, confirming that the protease is inactive in the absence of the NS2B cofactor.
Effect of pH on Enzymatic Activity-The WNV NS3 protease (WNV CF40.Gly.NS3pro) was assayed over a wide pH range from pH 5.5-11.0, using a variety of buffers suitable for each pH range: MES (pH 5.5-7.0), MOPS (pH 6.5-8.0), Tris-HCl (pH 7.5-9.5), CAPS (pH 10.0 -11.0). The optimal pH for proteolytic cleavage was determined to be pH 9.5 (Fig. 5A ). In the absence of enzyme, the substrate was resistant to hydrolysis above the optimal processing pH of 9.5, and was still intact at pH 12.0. The optimal processing pH of the WNV protease (pH 9.5) is comparable to the optimal processing pH (9.0) that we found previously for the Dengue-2 virus NS3 protease (6) .
Effect of Glycerol on Enzymatic Activity-We had previously found that glycerol enhances catalytic processing by Dengue NS3 protease (6) , an effect we attributed to minimizing enzyme aggregation (26) . We therefore examined the effect of varying glycerol concentrations (0 -50% v/v) in the final assay volume on catalytic rate of processing of FASGKR-pNA. There was a linear concentration dependence on glycerol (Fig. 5B) , consistent with increasing glycerol-promoting dissociation of aggregating enzyme molecules and increasing accessibility of the enzyme active site to substrate. While increasing glycerol content of the assay environment proved beneficial to processing of substrates, the increasing viscosity of aqueous glycerol limited the assay to 30% glycerol in the final assay volume.
Effect of Ionic Strength on Enzymatic Activity-The effect of increasing ionic strength was tested by adding NaCl (0 -200 mM) to the reaction medium. The results (Fig. 5C ) clearly show that increasing ionic strength inhibits the proteolytic processing of the substrate. High NaCl might conceivably be detrimental by competing with substrate and water molecules for occupancy of the substrate binding active site, thereby inhibiting substrate processing. Alternatively, NaCl is known to favor ␣-helicity in peptides, and thus may alter conformational equilibria of substrates in solution, rendering them less recognizable to the protease. It has been convincingly demonstrated elsewhere that all proteases only recognize their substrates and inhibitor analogues in an extended ␤-strand conformation (22, 27) . Thus, lower proportions of substrates in a ␤-strand conformation would reduce the catalytic turnover, as observed.
Enzyme Kinetics: Substrates and Inhibitor-The four peptide substrates, corresponding to the different NS2A-NS2B, NS2B-NS3, NS3-NS4A, NS4B-NS5 cleavage sites of the WNV RNA genome, were tested for their capacity to be cleaved by the WNV protease under the optimal processing conditions outlined above (50 mM ethanolamine buffer, pH 9.5; 30% glycerol; 1 mM CHAPS, no added NaCl, 37°C, final volume 200 l). The assay was conducted using eight different substrate concentrations ranging from 125 to 3000 M. ( Fig. 5D ) in order to calculate the binding affinity constant K m and the reaction rate k cat (ϭ V max /[E]). Kinetic data (Table I) suggested only small changes in processing rate (k cat ) between the four substrates, with the NS3-NS4A cleavage site being processed fastest and the NS2B-NS3 cleavage site processed slowest. The highest affinity substrate (lowest K m ) was the sequence corresponding to the NS3-NS4A cleavage site. The rank order for highest catalytic efficiency (k cat /K m ) of these pNA substrates was AcFASGKR-pNA (NS3-NS4A) Ͼ Ac-KPGLKR-pNA (NS4B-NS5) Ն Ac-DPNRKR-pNA (NS2A-NS2B) Ն Ac-LQYTKR-pNA (NS2B-NS3). By comparison, corresponding processing of Dengue pNA substrates by Dengue-2 CF40.Gly.NS3pro (6) displayed K m and k cat values that were lower than for the WNV substrates. This suggests greater catalytic efficiency (k cat /K m ) for substrate processing by the WNV NS3 protease compared with the analogous recombinant Dengue NS3 protease construct.
Based on this preference for the P6-P1 substrate sequence corresponding to NS3-NS4A, we also constructed Ac-FAS-GKR-H with a C-terminal aldehyde and found (Fig. 5E ) this to be a reasonably potent competitive inhibitor (IC 50 ϳ1 M) of catalytic processing of Ac-FASGKR-pNA by WNV CF40. Gly.NS3pro. This potency is despite the fact that the aldehyde exists in aqueous solution as an equilibrium mixture (Fig. 6) with a cyclic form, in which the side chain guanidine of Arg has condensed with aldehyde, and with acetal formed through hydration of the aldehyde. The free aldehyde is likely to be the active form of this inhibitor (28), but is not present above 5% in the mixture in aqueous solution, the bulk of the compound existing in the hydrate form of the aldehyde and in two diastereomeric hemi-aminal cyclic forms (Fig. 6) . The modest potency observed for this inhibitor may be a consequence of the unfavorable position of this equilibrium, with little of the active form of the inhibitor (free aldehyde) available for interaction with the active site serine hydroxyl group.
The effect of standard protease inhibitors on processing of the substrate Ac-FASGKR-pNA by WNV CF40.gly.NS3pro was also investigated (Fig. 7) . Standard serine protease inhibitors such as benzamidine, FUT-175, PMSF, leupeptin, and TLCK, failed to show any significant protease inhibition at concentrations of 100 M. Under the same conditions FASGKR-aldehyde was a significant inhibitor even at a concentration of 10 M (Fig. 7) .
Homology Modeling-In order to provide a structural basis for further investigations of the WNV protease, for which no current crystal structure exists, a homology structural model was generated based on the crystal structures of two flavivirus proteases, the Dengue virus NS3 protease (pdb1BEF and pdb1DF9) (9) , and the hepatitis C virus NS3 protease (pdb1A1Q) (8) . The Dengue virus NS3 and hepatitis C virus proteases were selected as a basis for the WNV protease model for their sequence homology (with Dengue NS3pro, Fig. 2 ) and structural homology (HCV, with lower sequence homology), providing a suitable reference for generating a WNV NS3 protease homology model. As the flaviviral NS3 proteases require a cofactor for activity, the HCV protease structure (pdb1A1Q) (8) containing the HCV NS4A cofactor was used for the WNV protease homology model, thus taking into account the role of the WNV NS2B cofactor in the activation of the WNV NS3 protease.
Whereas sequence identity between the HCV protease and WNV protease or HCV protease and Dengue viral protease was much less (14.5% and 15.5% respectively), the knowledge of high structural homology based on a previous study of HCV and Dengue virus proteases allowed additional structural reference for the generation of the model. Studies by Brinkworth et al. (25) elucidated a model of Dengue virus NS3 protease based on the HCV NS3 protease crystal structure, despite low sequence identity. This has since been confirmed by a crystal structure for Dengue virus NS3 protease (pdb1DF9), used in the current WNV homology model construction. Sequence alignment of the HCV protease and WNV protease or HCV protease and Dengue virus protease yielded 50 and 59% similarity respectively, giving insight into the structural similarity between the three proteases.
The HCV model with NS4A cofactor allowed the generation of a WNV protease and potential cofactor model not seen in the Dengue virus crystal structure. The Dengue NS3 crystal structure in complex with mung bean Bowman-Birk inhibitor (pdb1DF9) illustrated the key interactions in the active site of the Dengue NS3 protease. The Dengue NS3 structure provided a useful reference for the development of WNV protease-substrate interaction studies. Knowledge of endogenous cleavage sites was later used in substrate docking and active site studies, with a view to designing an early substrate-based inhibitor of the West Nile Virus protease.
Numerous models were generated, based on comparisons between the different structures and using different sequence alignment techniques, in order to examine different possibilities for the WNV protease structure. The final model used for analysis of putative substrate interactions in the active site was based on the Dengue NS3 protease complexed with the Bowman-Birk inhibitor (pdb1DF9, subunit B). The ␣-carbon traces of the WNV model and the Dengue-2 viral protease crystal structure were very similar. Based on the endogenous cleavage sites of the WNV NS3 protease, and their P1, P2 dibasic specificity, a four residue P3-P1Ј substrate (Thr-Lys-Arg-Gly) was docked into the active site of the WNV protease model in order to analyze the probable binding interactions between the substrate and WNV protease (Fig. 8) (Fig.  8) . The S2 subsite is fairly exposed, but a hydrogen bond may be formed between Lys at P2 and Asn 152 at S2. The catalytic triad is also exposed and lies adjacent to the P2 pocket. The P3 Thr residue exhibited a potential interaction with protease subsite S3 residues Gly 153 and Ile 155 (Fig. 8) . The P1Ј Gly residue may interact with protease subsite S1Ј by hydrogen bonding to Thr 132 and is in close proximity to Ala 36 (Fig. 8) . Analysis of these interactions and their relative importance suggested possible mutagenesis of the active site residues Ser 163 , Tyr 150 , Asp 129 , and Asn 152 . 4 
DISCUSSION
West Nile Virus infections have increased dramatically over the past decade and the associated morbidity and mortality have increased the urgency for antiviral therapies (29) . Rationally devised treatments for WNV infections might also become prototypes for developing antiviral therapies for other flavivirus infections. A single protease enzyme within the WNV genome is known to be responsible for critical virus-mediated post-translational cleavages of the polypeptide encoding all the structural and functional viral proteins that ultimately provide the replicative machinery for virus amplification and assembly 4 A range of inhibitors were tested for their activity (ϮS.E.) against WNV CF40.Gly.NS3pro. Test compounds were preincubated with 0.5 M WNV CF40.Gly.NS3pro for 10 min at 37°C followed by addition of the substrate Ac-FASGKR-pNA substrate (500 M) in 50 mM glycine-NaOH buffer, pH 9.0, 30% glycerol and 1 mM CHAPS. Inhibitors tested were: 1, no inhibitor control; 2, benzamidine (100 M); 3, FUT-175 (100 M); 4, PMSF (100 M); 5, FASGKR-aldehyde inhibitor (10 M); 6, leupeptin (100 M); 7, TLCK (100 M).
FIG. 8.
Homology-modeled structure of West Nile Virus NS3 protease showing putative interactions between WNV-NS3 protease active site residues (S3, S2, S1, S1) and substrate.
into new virus particles. Inhibition of that protease has the capacity therefore to prevent viral replication. The present study was aimed at producing and characterizing the first catalytically active recombinant WNV protease.
To construct a recombinant West Nile Virus protease, we took advantage of the sequence homology between WNV and Dengue-2 virus NS2B-NS3 proteins (Fig. 2) and our previous work that successfully led to a recombinant Dengue virus protease (6) . In summary, we adapted the corresponding WNV sequences of the putative minimum NS2B cofactor domain and of the minimum NS3 protease domain and linked them together with a nonapeptide (G 4 SG 4 ) replacement for the NS2B-NS3A native cleavage site. The result was a catalytically active recombinant WNV protease, designated WNV CF40.Gly.-NS3pro, which is active only with the appended cofactor domain.
We characterized the enzyme processing properties of the recombinant WNV protease, identifying optimal buffers, pH, and diluents to maximize proteolytic activity. The assay, involving the use of hexapeptide substrates corresponding to P6-P1 segments of cleavage sites within the WNV genome fused to a chromogenic moiety (para-nitroanilide) at P1Ј, has the potential for rapidly screening prospective inhibitors of the enzyme. Indeed, based on one of the substrates examined, we also generated the first small molecule inhibitor (IC 50 1 M) of the WNV protease.
A striking feature of the enzymatic activity was the similarity between catalytic properties of the recombinant proteases of Dengue virus and West Nile Virus. The high pH (8 -10) required for processing is unusual and cannot yet be satisfactorily explained, but may indicate a level of virus-mediated control over replication, since processing at physiological pH would be 1% of the measured rates at pH 9.0.
The native cleavage sites that are processed by WNV protease in vivo (Fig. 1) feature two conserved basic residues at positions P1 and P2 (Arg, Lys, respectively, Fig. 4 ) and a small residue at P1Ј (Gly, Ser), indicating a signal sequence for the cleavage of the WNV genome by its NS2B-NS3 protease. This dibasic recognition sequence is almost completely conserved throughout the flaviviral proteases and is unusual in comparison with host cellular enzymes. Indeed we have now shown for both the Dengue-2 (6) and WNV virus proteases (Fig. 7) that a panel of conventional serine protease inhibitors was inactive against that protease. This feature promises novelty for the design of potent inhibitors that may be selective for flavivirus proteases over host cellular proteases. Realization of a potent and selective inhibitor of WNV protease may result in an attractive lead for development of an antiviral treatment for WNV, and perhaps with potential for broad spectrum inhibition of flaviviruses in general.
Toward further studies, aimed at developing even more potent and selective inhibitors of WNV protease as candidate antiviral drugs, we also created a three-dimensional structural model of the protease. That model suggests binding sites in the protease for both the NS2B cofactor and small molecule substrates/inhibitors that can occupy the active site, and reveals putative enzyme-ligand interactions that should provide valuable insights for inhibitor development. This information could conceivably be combined with the known requirement in protease active sites of the extended ␤-strand ligand conformation (22, 27) , 3 and the growing number of ␤-strand mimetics (30, 31) becoming available as templates for design of substrate-based inhibitors of proteases.
